Abstract:Non-steroidal anti-inflammatory drugs (NSAIDs) can be used as part of a multimodal approach to managing acute pain. Administering NSAIDs by intramuscular (IM) or intravenous (IV) injection allows them to be used in patients who are nil-by-mouth, who cannot swallow, and to allow a more rapid onset compared to the oral route. Current paramedic practice in the UK does not generally allow for the use of an NSAID given by IM or IV injection for acute pain. While paramedics may administer paracetamol and morphine in… Show more
“…BMP-2 promotes the expression of other BMP genes in the bone cell differentiation process; furthermore, through paracrine signaling with other BMPs, BMP-2 prompts cell differentiation and bone formation during the remodeling process [24]. Ketorolac belongs to the nonsteroidal anti-inflammatory drug (NSAID) class and is an FDAapproved medication used for the management of acute moderate to severe pain [25] and is commonly used for postoperative pain management. Amoxicillin, a moderate-spectrum, bacteriolytic, β-lactam antimicrobial agent in the aminopenicillin family, is used to cure susceptible Gram-positive and Gram-negative bacteria [26] and has been used to treat bacterial infections, including tonsillitis, bronchitis, pneumonia, and infections of the ear, nose, throat, skin, and urinary tract.…”
An alveolar cleft is a bone defect in the maxillary arch. Although the use of autologous iliac bone grafts to repair alveolar clefts is the preferred treatment method, donor-site morbidity remains a concern. In this study, we incorporated bone morphogenetic protein (BMP), an antimicrobial agent, and an analgesic into nanofibrous scaffolds for alveolar cleft therapy. Three-dimensional (3D) printing and coaxial electrospinning techniques were used to fabricate the scaffolds. BMP-2, ketorolac, and amoxicillin were used as the growth factor, analgesic, and antimicrobial agent, respectively. The in vitro properties of the nanofibrous scaffolds were characterized, and in vivo efficacy was evaluated in a rat alveolar-cleft model. The empirical data indicated that the biomolecule-incorporated scaffolds offered extended discharge of BMP-2, amoxicillin, and ketorolac for >4 weeks. The animal test outcomes also demonstrated favorable bone healing at the cleft site. Biomolecule- and drug-incorporated nanofibrous scaffolds demonstrated their efficacy in alveolar cleft treatment.
“…BMP-2 promotes the expression of other BMP genes in the bone cell differentiation process; furthermore, through paracrine signaling with other BMPs, BMP-2 prompts cell differentiation and bone formation during the remodeling process [24]. Ketorolac belongs to the nonsteroidal anti-inflammatory drug (NSAID) class and is an FDAapproved medication used for the management of acute moderate to severe pain [25] and is commonly used for postoperative pain management. Amoxicillin, a moderate-spectrum, bacteriolytic, β-lactam antimicrobial agent in the aminopenicillin family, is used to cure susceptible Gram-positive and Gram-negative bacteria [26] and has been used to treat bacterial infections, including tonsillitis, bronchitis, pneumonia, and infections of the ear, nose, throat, skin, and urinary tract.…”
An alveolar cleft is a bone defect in the maxillary arch. Although the use of autologous iliac bone grafts to repair alveolar clefts is the preferred treatment method, donor-site morbidity remains a concern. In this study, we incorporated bone morphogenetic protein (BMP), an antimicrobial agent, and an analgesic into nanofibrous scaffolds for alveolar cleft therapy. Three-dimensional (3D) printing and coaxial electrospinning techniques were used to fabricate the scaffolds. BMP-2, ketorolac, and amoxicillin were used as the growth factor, analgesic, and antimicrobial agent, respectively. The in vitro properties of the nanofibrous scaffolds were characterized, and in vivo efficacy was evaluated in a rat alveolar-cleft model. The empirical data indicated that the biomolecule-incorporated scaffolds offered extended discharge of BMP-2, amoxicillin, and ketorolac for >4 weeks. The animal test outcomes also demonstrated favorable bone healing at the cleft site. Biomolecule- and drug-incorporated nanofibrous scaffolds demonstrated their efficacy in alveolar cleft treatment.
“…This includes, in particular, 1 which acts as an inhibitor of the HSP90 protein for regulation of the dopaminergic pathway in Parkinson's disease, 5 2 which blocks CFTR protein for the treatment of severe diarrhea, 6 3 for the prevention of cellular replication of hepatitis C virus (HCV), 7 and 4, an inhibitor of histone deacetylases that play an important role in the regulation of gene expression. 8 Also, ketorolac 5 is a nonsteroidal anti-inflammatory drug with analgesic activity 9 and molindone 6 (Moban) has been used in the United States as an antipsychotic for the treatment of schizophrenia. 10 The synthesis of differently substituted pyrroles has been the subject of a great deal of work and there are numerous reviews describing various strategies.…”
Complimentary to classical hydroboration and boron-Wittig reactions, a new, efficient access to cyclic 1,3-dienyl boronic esters has been developed via diene or triene metathesis. Subsequently, fused pyrroles were synthesized with a broad substrate scope from the reaction of cyclic 1,3-dienyl boronic esters with arylnitroso compounds using a one-pot hetero-Diels−Alder/ring contraction sequence.
“…Ketorolac (KTR) is one of the most popularly used analgesic drugs all over the world. It is non-steroidal anti-inflammatory drug (NSAID) and member of heterocyclic acetic acid derivatives [1].KTR shows analgesic, anti-inflammation, and antipyretic activities [2]. It is safe and effective analgesic agent for the short-term management of moderate to severe pain and can be used as an alternative to opioid therapy [3].…”
Background Ketorolac (KTR) is used as an analgesic drug with an efficacy close to that of the opioid family. It is mainly used for the short term treatment of post-operative pain. It can inhibit the prostaglandin synthesis by blocking cyclooxygenase (COX). Methods In this investigation, the inherent stability and biochemical interaction of Ketorolac (KTR) and its degradation products have been studiedon the basis of quantum mechanical approaches. Density functional theory (DFT) with B3LYP/ 6-31G (d) has been employed to optimize the structures. Thermodynamic properties, frontier molecular orbital features, dipole moment, electrostatic potential, equilibrium geometry, vibrational frequencies and atomic partial charges of these optimized structureswere investigated. Molecular docking has been performed against prostaglandin H2 (PGH2) synthase protein 5F19 to search the binding affinity and mode(s). ADMET prediction has performed to evaluate the absorption, metabolism and carcinogenic properties.Results The equilibrium geometry calculations support the optimized structures. Thermodynamic results disclosed the thermal stability of all structures. From molecular orbital data, all the degradents are chemically more reactive than parent drug (except K3). However, the substitution of carboxymethyl radicalin K4 improved the physicochemical properties and binding affinity. ADMET calculations predict the improved pharmacokinetic and non-carcinogenic properties of all degradents. Conclusion Based on physicochemical, molecular docking, and ADMET calculation, this study can be helpful to understand the biochemical activities of Ketorolac and its degradents and to design a potent analgesic drug.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.